Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$4.37
$4.92
$2.60
$11.99
$4.24M1.5526,396 shs35,704 shs
Biocept, Inc. stock logo
BIOC
Biocept
$0.97
$0.32
$27.00
$1.14M0.69764,067 shs751,400 shs
Celcuity, Inc. stock logo
CELC
Celcuity
$13.63
+0.1%
$11.76
$7.58
$19.77
$515.74M0.45275,957 shs171,535 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19171,031 shs4.12 million shs
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$17.04
-0.5%
$17.69
$4.66
$34.05
$66.59M1.66134,027 shs477,598 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00%0.00%0.00%0.00%0.00%
Biocept, Inc. stock logo
BIOC
Biocept
0.00%0.00%0.00%0.00%0.00%
Celcuity, Inc. stock logo
CELC
Celcuity
+0.07%-1.16%+9.13%+47.67%-19.11%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+4.17%-69.91%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
+0.53%+9.32%+11.09%+50.13%+39.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
2.302 of 5 stars
3.61.00.00.02.72.50.0
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00
N/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
0.00
N/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
3.17
Buy$28.40108.36% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENZ, CELC, BIOC, ANPC, and MGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/30/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$1.75M2.42N/AN/A($1.41) per share-3.10
Biocept, Inc. stock logo
BIOC
Biocept
$25.86M0.00N/AN/A$15.60 per share0.00
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$4.46M14.93N/AN/A$6.78 per share2.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
-$14.77MN/A0.00N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/A
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/A

Latest ENZ, CELC, BIOC, ANPC, and MGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/A
0.32
0.32
Biocept, Inc. stock logo
BIOC
Biocept
2.88
1.81
1.70
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.20
4.23
4.23

Institutional Ownership

CompanyInstitutional Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
45.84%
Biocept, Inc. stock logo
BIOC
Biocept
N/A
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
26.22%
Biocept, Inc. stock logo
BIOC
Biocept
1.61%
Celcuity, Inc. stock logo
CELC
Celcuity
15.77%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
86970,000715,000Not Optionable
Biocept, Inc. stock logo
BIOC
Biocept
502.63 million2.58 millionNot Optionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.90 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
453.91 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fresh2 Group stock logo

Fresh2 Group NASDAQ:ANPC

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

Biocept stock logo

Biocept NASDAQ:BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Celcuity stock logo

Celcuity NASDAQ:CELC

$13.63 +0.01 (+0.07%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$13.71 +0.08 (+0.59%)
As of 07/11/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Miragen Therapeutics stock logo

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.